European major stock indices open lower; Germany's DAX 30 falls 0.05%, UK's FTSE 100 falls 0.07%, French CAC 40 falls 0.01%, Euro Stoxx 50 falls 0.02%.

European major stock indices open lower; Germany's DAX 30 falls 0.05%, UK's FTSE 100 falls 0.07%, French CAC 40 falls 0.01%, Euro Stoxx 50 falls 0.02%.

European stock markets opened the week with mixed performance on Monday, with the Stoxx Europe 600 edging 0.13% lower. Germany's DAX declined 0.48%, the FTSE 100 gained 0.11%, France's CAC fell 0.3%, and the Swiss Market Index increased 0.14% .

The European Commission's Economic Sentiment Indicator for September rose 0.5 percentage points in the EU and 0.6 points in the euro area, indicating a slight improvement in consumer confidence. However, the indicator remains "markedly below" its historical average since April .

In corporate news, Banco Bilbao Vizcaya Argentaria (BBVA) raised its offer to acquire Banco Sabadell by 10% to 17 billion euros ($20 billion). Under the new bid, BBVA will offer one share for every 4.8376 Banco Sabadell shares, valuing Banco Sabadell shares at 3.39 euros apiece . Shares of Banco Bilbao Vizcaya Argentaria lost 2.44%, while Banco Sabadell's stock fell close to 4% in Madrid trading.

Stellantis reported unauthorized access to a third-party service provider's platform, exposing contact information but not financial data. Shares of Stellantis fell 2.6% in Paris .

Automotive stocks were the biggest losers on the German market after Porsche AG delayed its electric vehicle model rollout and slashed its 2025 profitability forecast. The German automaker cited weak demand and said the delays would impact its 2025 operating profit by up to 1.8 billion euros. Shares of Porsche AG dropped 4.65% in Frankfurt .

BP halted development of a planned standalone biofuels facility at its Rotterdam refinery in the Netherlands, Reuters reported. The decision comes amid a series of scrapped projects as oil majors scale back renewable fuel ambitions amid soft demand . Shares of the British oil and gas company were up nearly 1% on the FTSE 100 in London.

AstraZeneca received a recommendation for approval of Koselugo in the European Union to treat neurofibromatosis type 1 from the European Medicines Agency's Committee for Medicinal Products for Human Use. The decision was based on a phase 3 trial that showed "a statistically significant objective response rate." Shares of AstraZeneca gained 1.7% in London .